Is KLOW approved or legal?

No. KLOW is not an approved drug, and none of its four components (GHK-Cu, BPC-157, TB-500, KPV) is FDA-approved for human use. The blend itself has never been studied in clinical trials. It is sold and discussed strictly as a research chemical, not for human consumption, and TB-500/thymosin beta-4 is also banned in competitive sport (WADA).

What is the half-life of KLOW?

There is no combined half-life because it is a blend of four peptides with very different kinetics. GHK-Cu and BPC-157 clear from plasma quickly (roughly under 30-60 minutes), KPV is a rapidly cleared tripeptide, and TB-500 is longer-acting and typically dosed weekly. No pharmacokinetic study exists for the blend as a whole.

Is there human clinical evidence that KLOW works?

Not for the blend. The supporting research is almost entirely preclinical (animal and in-vitro) at the component level, with the partial exception of topical GHK-Cu in cosmetic studies. Benefits reported for the combination are anecdotal.

How is KLOW administered?

Community sources describe subcutaneous injection after reconstitution with bacteriostatic water, and occasionally topical use for the GHK-Cu component. This is anecdotal reference information, not a dosing recommendation or medical advice.

What are the main safety concerns?

There is no human safety data for the combination. Concerns include injection-site reactions, possible copper overexposure from GHK-Cu, unknown long-term effects, theoretical tumor-growth risk from the pro-angiogenic components, and contamination risk from non-pharmaceutical material. Consult a qualified clinician before considering any use.

Blend

KLOW

Also known as: KLOW blend, KLOW stack, GHK-Cu/BPC-157/TB-500/KPV blend

Research-only 4-peptide blend (GHK-Cu, BPC-157, TB-500, KPV) studied for tissue repair and inflammation; human evidence is limited.

Last updated July 11, 2026

Buy KLOW

What's in this blend

GHK-Cu — 50mg (details)
BPC-157 — 10mg (details)
TB-500 — 10mg (details)
KPV — 10mg (details)

Overview

KLOW is a fixed-ratio blend of four research peptides: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic gastric pentadecapeptide), TB-500 (a synthetic fragment of thymosin beta-4), and KPV (the C-terminal tripeptide of alpha-MSH). A common vial format is 80 mg total (50 mg GHK-Cu, 10 mg each of BPC-157, TB-500, and KPV). It is marketed within the peptide community as a combined "repair and recovery" stack rather than as a single characterized drug. The rationale for the combination is mechanistic complementarity: GHK-Cu and TB-500 are associated with extracellular-matrix remodeling and angiogenesis, BPC-157 with cytoprotection and soft-tissue repair signaling, and KPV with dampening NF-kB-driven inflammation. None of these claims for the blend as a whole have been validated in controlled human trials; the supporting data come almost entirely from preclinical (animal and in-vitro) studies of the individual components. KLOW is sold and discussed strictly as a research chemical. None of its components is an FDA-approved drug for human use, and the blend itself has never been studied as a fixed combination in peer-reviewed clinical research. The information here is a research reference, not medical advice or an endorsement of human consumption.

How it works

KLOW combines four distinct mechanisms. GHK-Cu delivers copper to tissues and modulates gene expression linked to collagen, elastin, and glycosaminoglycan synthesis, fibroblast activity, angiogenesis, and antioxidant response. TB-500 (thymosin beta-4 fragment) sequesters monomeric G-actin via its LKKTETQ motif, regulating cytoskeletal remodeling that underlies cell migration, re-epithelialization, and capillary formation. BPC-157 is reported in animal models to promote tendon-fibroblast outgrowth, survival, and migration (FAK-paxillin pathway) and angiogenesis via VEGFR2/nitric-oxide signaling. KPV, the alpha-MSH(11-13) fragment, exerts anti-inflammatory effects largely through inhibition of NF-kB signaling and reduced pro-inflammatory cytokine output (TNF-alpha, IL-1beta, IL-6), reportedly via a receptor-independent intracellular route. The proposed synergy is that matrix-building/angiogenic actions are paired with inflammation control, but combined synergy has not been demonstrated in controlled studies.

Researched effects

Clinical GHK-Cu improves visible skin parameters (firmness, elasticity, thickness, fine lines) in topical aesthetic studies
Preclinical GHK-Cu accelerates wound closure, angiogenesis, and collagen/ECM remodeling
Preclinical BPC-157 improves tendon, muscle, ligament, and bone healing outcomes in rodent models
Preclinical TB-500 promotes cell migration, re-epithelialization, and angiogenesis in wound and cardiac-injury models
Preclinical KPV reduces NF-kB-driven inflammation and pro-inflammatory cytokines in vitro and in animal models
Anecdotal Users report faster soft-tissue/injury recovery and skin/hair improvements when using the blend

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established clinical dosing in humans for the KLOW blend. There are no controlled human trials of this fixed combination. The strongest human data are for topical GHK-Cu in cosmetic/dermatology studies; BPC-157, TB-500, and KPV have essentially no validated human dosing from peer-reviewed trials.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only, not medical advice or instruction. Community guides (peptide forums and r/Peptides-adjacent sources) commonly describe reconstituting an 80 mg vial with 2-3 mL bacteriostatic water and dosing once daily subcutaneously, often framed as a 4-week loading phase followed by 4-8 weeks of daily or 5x/week maintenance, then a break. Per-component figures anecdotally cited include roughly: GHK-Cu ~1-2 mg/day, BPC-157 ~250-500 mcg/day, KPV ~250-500 mcg/day, and TB-500 ~2 mg/week (sometimes with a higher loading week). Because the components are in a fixed ratio, hitting one component's reported range will push others above or below their typical standalone ranges; some users supplement standalone TB-500. These figures are unverified, vary widely between sources, and should not be interpreted as safe or effective doses.

Half-life: Varies by component: GHK-Cu and BPC-157 have very short plasma half-lives (roughly under ~30-60 minutes); TB-500/thymosin beta-4 is longer-acting and typically dosed weekly; KPV is a small, rapidly cleared tripeptide. No combined pharmacokinetic profile exists for the blend.
Routes: subcutaneous, topical

Safety & side effects

The KLOW blend has no human safety data as a combination, and none of its components is FDA-approved for human use. Reported and theoretical concerns include injection-site reactions (redness, pain, swelling), and for GHK-Cu the risk of excess copper exposure with high or prolonged dosing (copper accumulation, nausea). KPV and alpha-MSH fragments carry theoretical immunomodulatory effects. BPC-157 and TB-500 lack long-term human safety data, including unknown effects on tumor growth given their pro-angiogenic and pro-migratory mechanisms; TB-500 and similar compounds are prohibited in competitive sport (WADA). Sterility and contamination from non-pharmaceutical research material are real risks. Anyone with cancer history, who is pregnant or breastfeeding, or on other therapies should be especially cautious. This is not medical advice.

Research summary

The evidence base for KLOW is best understood at the component level, because the blend itself has never been evaluated in peer-reviewed clinical or preclinical studies. Of the four, GHK-Cu has the most human data, mainly from topical cosmetic and dermatology research showing improvements in skin firmness, elasticity, and collagen markers, supported by extensive preclinical wound-healing and gene-modulation work. TB-500 (thymosin beta-4) has a substantial preclinical literature on actin sequestration, cell migration, and angiogenesis, including the frequently cited cardiac-repair work, but lacks robust human efficacy trials. BPC-157 is supported almost entirely by rodent studies of tendon, muscle, ligament, and bone healing; systematic reviews consistently note the near-absence of human clinical data and call its musculoskeletal benefits unproven in people. KPV is supported by in-vitro and animal anti-inflammatory studies centered on NF-kB inhibition and cytokine suppression, again without controlled human efficacy trials. Taken together, the mechanistic rationale for combining matrix-building, angiogenic, and anti-inflammatory peptides is plausible, but "plausible mechanism" is not the same as demonstrated efficacy or safety. The honest assessment is that KLOW is an experimental, research-use-only blend with mostly preclinical support, meaningful unknowns around long-term safety and combined pharmacology, and community enthusiasm that outpaces the published evidence.

FAQ

Is KLOW approved or legal?: No. KLOW is not an approved drug, and none of its four components (GHK-Cu, BPC-157, TB-500, KPV) is FDA-approved for human use. The blend itself has never been studied in clinical trials. It is sold and discussed strictly as a research chemical, not for human consumption, and TB-500/thymosin beta-4 is also banned in competitive sport (WADA).
What is the half-life of KLOW?: There is no combined half-life because it is a blend of four peptides with very different kinetics. GHK-Cu and BPC-157 clear from plasma quickly (roughly under 30-60 minutes), KPV is a rapidly cleared tripeptide, and TB-500 is longer-acting and typically dosed weekly. No pharmacokinetic study exists for the blend as a whole.
Is there human clinical evidence that KLOW works?: Not for the blend. The supporting research is almost entirely preclinical (animal and in-vitro) at the component level, with the partial exception of topical GHK-Cu in cosmetic studies. Benefits reported for the combination are anecdotal.
How is KLOW administered?: Community sources describe subcutaneous injection after reconstitution with bacteriostatic water, and occasionally topical use for the GHK-Cu component. This is anecdotal reference information, not a dosing recommendation or medical advice.
What are the main safety concerns?: There is no human safety data for the combination. Concerns include injection-site reactions, possible copper overexposure from GHK-Cu, unknown long-term effects, theoretical tumor-growth risk from the pro-angiogenic components, and contamination risk from non-pharmaceutical material. Consult a qualified clinician before considering any use.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.